The health insurance death spiral

I am scared.  Really scared.  I live and breathe the health care delivery and finance model in the U.S. every day, and I believe we are circling the drain.  Although this analogy can apply to many areas of our system, there is one cycle I am referring to specifically. 

Most providers (hospitals, doctors, pharmaceutical manufacturers) are in business for one reason and one reason only — to make money.  And while they may fall back on the philanthropic or social aspects of what they do, that does not speak to their why.  I know this because every action supports this.  I was at an industry function recently in San Diego, and there happened to be a friend of another attendee in town who was a pharmaceutical rep.  I casually asked him how he feels about the rising and astronomically high costs of many drugs.  He said “Do you want my company to continue to fund the research and development into new life saving drugs that we come up with each year?”  A common scapegoat.  I said of course I do.  But I happen to know that your company spends almost twice as much on marketing the drugs than they do on R&D, “So how about they cut back on marketing alone?” I said.  What’s interesting is they amortize their R&D over every country they sell their drugs in, about 44, according to my research.  But the marketing to consumers can only be done in two countries: the U.S. and New Zealand.   No other country allows it.  So to say there is no room to dramatically reduce costs without even touching the R&D budget is a huge misnomer.